Page 163 - Access Program News Today

– Enrolled Patients May Continue Receiving Study Medicine – – Studies in Solid Tumors Unaffected – ...

FDA has placed a partial clinical hold on Gilead Sciences Inc (NASDAQ: GILD) initiation of new patients in U.S.

The FDA has placed another partial clinical hold on the enrollment of new patients in United States clinical trials evaluating the potential first-in-class investigational anti-CD47 immunotherapy magrolimab for the treatment of acute myeloid leukemia.

A significant turnaround materialized for Blue Apron (NYSE: APRN), sparking unseen investor support: a brief overview on developments.

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2023 Earnings Call Transcript August 15, 2023 TFF Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.14 EPS, expectations were $0.2. Operator: Good morning, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Second Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being […]

Delcath Systems, Inc. announced that the US Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable... -Yesterday at 09:10 pm- MarketScreener

A deconstructed view on Delcath Systems' (NASDAQ: DCTH) latest FDA approval and key points that are important for investors to understand.

Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

(RTTNews) - The U.S. Food and Drug Administration approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult...